Targeted therapy model of treatment dealt stunning blow

A study appearing in this week's New England Journal of Medicine may deal a massive blow to the field of personalized cancer treatment and to the hopes of doctors and patients alike.

Researchers at Cancer Research UK London Research Institute have discovered that the hopes of taking a tumor biopsy and basing treatment on that sole biopsy is insufficient because it fails to give an accurate portrait of the tumor's genetic code, as there may be places in the code where different genes are active or are mutated than what is uncovered in the biopsy.

This means that a single biopsy can not possibly represent the full genetic sequence of a tumor, and basing any specific targeted treatment options on it will likely result in relapse.

"The deeper you go, the more you find," said one researcher.

It remains unclear if multiple biopsies would produce anything more workable.

This study focused on kidney cancer but it's not a stretch to imagine this to be true across many if not all cancers.

Source: NEJM

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap